Sen-Jam Pharmaceutical TAKES THE STAGE AT EUROPEAN BIOPHARMA OBESITY INNOVATION FORUM

Category 1 (1)

Public Health Impact | Science Beyond the Solutions | The Sen-Jam Perspective

Sachs Biopharma Event June

We could not be more proud of Jackie—our brilliant Female Founder and the only woman on today’s stage—and of our team’s progress in advancing science that can truly make a difference. It’s moments like these that underscore Sen-Jam’s bold and growing role in advancing breakthrough science to improve global health outcomes.

Thank you for your continued belief in our mission. The future is bright, and we’re just getting started.

June 11, 2025 – This past week, our executive team has been on the ground in Europe, connecting with the scientific and biopharma community—and helping to shape the conversation around the future of metabolic health.

Today, we had the honor of attending the Sachs European Biopharma Obesity Innovation Forum in Leipzig, Germany—a gathering of some of the brightest minds working to combat one of the world’s most urgent health crises.

The World Health Organization projects that by 2035, over half of the global population will be overweight or obese. The urgency for innovation has never been greater.

At today’s forum, our Co-Founder and Chief Clinical Officer, Jackie Iversen, RPh, MS, took center stage—not only delivering a powerful 20-minute presentation on Sen-Jam’s emerging role in addressing metabolic disorders, but also joining a live panel alongside Big Pharma leaders to discuss advancements in CardioRenal, Metabolic, and Obesity platforms.

In the video below, you’ll see a short clip of Jackie’s perspective on how biomarkers can help drive solutions across multiple therapeutic areas—an approach core to our work at Sen-Jam.

Recent Posts
Mask Group (20)

Patent Milestone and Stability Data Strengthen Licensing Value of SJP-002C

One year ago, we filed a provisional patent application for our Upper Respiratory Infection Therapeutic – SJP-002C, covering the novel manufacturing process for our dual-acting oral therapy…
Group 1000001207 (1)

Behind the Breakthrough: Strategic Insights from Sen-Jam’s Executive Leade...

In March 2025, Sen-Jam Pharmaceutical hosted a pivotal webinar in collaboration with Destum Partners, a premier strategic advisory firm known for driving success in biotech partnerships, licensing, and M&A…
Group 1000001074

Sen-Jam Pharmaceutical: Revolutionizing Inflammatory Care with Proprietary PAIR ...

HUNTINGTON, N.Y., Jan. 13, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical is proud to announce a pivotal moment in its mission to transform the way the world heals by tackling inflammation at its source…

Media Inquiry